Condition: Malignant Neoplasm · Sponsor: Merck Sharp & Dohme LLC
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Alaska Womens Cancer Care ( Site 0037) | Anchorage, Alaska, United States | Recruiting |
| Mount Sinai Cancer Center ( Site 0009) | Miami Beach, Florida, United States | Recruiting |
| TRIALS 365 ( Site 0022) | Shreveport, Louisiana, United States | Recruiting |
| Mary Lanning Healthcare ( Site 0019) | Hastings, Nebraska, United States | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0021) | Hackensack, New Jersey, United States | Recruiting |
| Rockefeller Outpatient Pavilion ( Site 0002) | New York, New York, United States | Recruiting |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0008) | Columbus, Ohio, United States | Recruiting |
| Baylor College of Medicine Medical Center ( Site 0004) | Houston, Texas, United States | Recruiting |
| Harris Health System ( Site 0040) | Houston, Texas, United States | Recruiting |
| Mays Cancer Center ( Site 0039) | San Antonio, Texas, United States | Recruiting |
| Hospital Aleman ( Site 0301) | Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina | Recruiting |
| Centro Medico Dr. Doreski - Fundación Respirar ( Site 0302) | Buenos Aires, Buenos Aires F.D., Argentina | Recruiting |
+ 46 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06979596